252 related articles for article (PubMed ID: 31264276)
1. Palbociclib, a selective CDK4/6 inhibitor, restricts cell survival and epithelial-mesenchymal transition in Panc-1 and MiaPaCa-2 pancreatic cancer cells.
Rencuzogulları O; Yerlikaya PO; Gürkan AÇ; Arısan ED; Telci D
J Cell Biochem; 2020 Jan; 121(1):508-523. PubMed ID: 31264276
[TBL] [Abstract][Full Text] [Related]
2. Alisertib induces cell cycle arrest and autophagy and suppresses epithelial-to-mesenchymal transition involving PI3K/Akt/mTOR and sirtuin 1-mediated signaling pathways in human pancreatic cancer cells.
Wang F; Li H; Yan XG; Zhou ZW; Yi ZG; He ZX; Pan ST; Yang YX; Wang ZZ; Zhang X; Yang T; Qiu JX; Zhou SF
Drug Des Devel Ther; 2015; 9():575-601. PubMed ID: 25632225
[TBL] [Abstract][Full Text] [Related]
3. Cdk4/6 inhibition induces epithelial-mesenchymal transition and enhances invasiveness in pancreatic cancer cells.
Liu F; Korc M
Mol Cancer Ther; 2012 Oct; 11(10):2138-48. PubMed ID: 22869556
[TBL] [Abstract][Full Text] [Related]
4. POTEE stimulates the proliferation of pancreatic cancer by activating the PI3K/Akt/GSK-3β/β-catenin signaling.
Hao Q; Gao L; Niu W; Chen L; Zhang P; Chen Z
Biofactors; 2020 Jul; 46(4):685-692. PubMed ID: 32589786
[TBL] [Abstract][Full Text] [Related]
5. Combined Inhibition of CDK4/6 and PI3K/AKT/mTOR Pathways Induces a Synergistic Anti-Tumor Effect in Malignant Pleural Mesothelioma Cells.
Bonelli MA; Digiacomo G; Fumarola C; Alfieri R; Quaini F; Falco A; Madeddu D; La Monica S; Cretella D; Ravelli A; Ulivi P; Tebaldi M; Calistri D; Delmonte A; Ampollini L; Carbognani P; Tiseo M; Cavazzoni A; Petronini PG
Neoplasia; 2017 Aug; 19(8):637-648. PubMed ID: 28704762
[TBL] [Abstract][Full Text] [Related]
6. Plumbagin induces cell cycle arrest and autophagy and suppresses epithelial to mesenchymal transition involving PI3K/Akt/mTOR-mediated pathway in human pancreatic cancer cells.
Wang F; Wang Q; Zhou ZW; Yu SN; Pan ST; He ZX; Zhang X; Wang D; Yang YX; Yang T; Sun T; Li M; Qiu JX; Zhou SF
Drug Des Devel Ther; 2015; 9():537-60. PubMed ID: 25632222
[TBL] [Abstract][Full Text] [Related]
7. AKT/GSK-3β/β-catenin signaling pathway participates in erythropoietin-promoted glioma proliferation.
Tang Z; Yang G; Wang X; Chen F; Liao Z; Zhang Z; Liu Z; Zeng W; Fang M; Wang W; Sun X; Huo G
J Neurooncol; 2020 Sep; 149(2):231-242. PubMed ID: 32909117
[TBL] [Abstract][Full Text] [Related]
8. Anti-cell growth and anti-cancer stem cell activity of the CDK4/6 inhibitor palbociclib in breast cancer cells.
Kishino E; Ogata R; Saitoh W; Koike Y; Ohta Y; Kanomata N; Kurebayashi J
Breast Cancer; 2020 May; 27(3):415-425. PubMed ID: 31823286
[TBL] [Abstract][Full Text] [Related]
9. Lucidone Promotes the Cutaneous Wound Healing Process via Activation of the PI
Yang HL; Tsai YC; Korivi M; Chang CT; Hseu YC
Biochim Biophys Acta Mol Cell Res; 2017 Jan; 1864(1):151-168. PubMed ID: 27816443
[TBL] [Abstract][Full Text] [Related]
10. Troglitazone ameliorates high glucose-induced EMT and dysfunction of SGLTs through PI3K/Akt, GSK-3β, Snail1, and β-catenin in renal proximal tubule cells.
Lee YJ; Han HJ
Am J Physiol Renal Physiol; 2010 May; 298(5):F1263-75. PubMed ID: 20015942
[TBL] [Abstract][Full Text] [Related]
11. Dual Inhibition of CDK4/6 and PI3K/AKT/mTOR Signaling Impairs Energy Metabolism in MPM Cancer Cells.
Bonelli M; Terenziani R; Zoppi S; Fumarola C; La Monica S; Cretella D; Alfieri R; Cavazzoni A; Digiacomo G; Galetti M; Petronini PG
Int J Mol Sci; 2020 Jul; 21(14):. PubMed ID: 32708306
[No Abstract] [Full Text] [Related]
12. Targeting Cyclin-Dependent Kinases in Synovial Sarcoma: Palbociclib as a Potential Treatment for Synovial Sarcoma Patients.
Vlenterie M; Hillebrandt-Roeffen MH; Schaars EW; Flucke UE; Fleuren ED; Navis AC; Leenders WP; Versleijen-Jonkers YM; van der Graaf WT
Ann Surg Oncol; 2016 Sep; 23(9):2745-52. PubMed ID: 27334220
[TBL] [Abstract][Full Text] [Related]
13. The CDK4/6 inhibitor palbociclib synergizes with irinotecan to promote colorectal cancer cell death under hypoxia.
Zhang J; Zhou L; Zhao S; Dicker DT; El-Deiry WS
Cell Cycle; 2017 Jun; 16(12):1193-1200. PubMed ID: 28486050
[TBL] [Abstract][Full Text] [Related]
14. Reg4-induced mitogenesis involves Akt-GSK3β-β-Catenin-TCF-4 signaling in human colorectal cancer.
Bishnupuri KS; Sainathan SK; Bishnupuri K; Leahy DR; Luo Q; Anant S; Houchen CW; Dieckgraefe BK
Mol Carcinog; 2014 Feb; 53 Suppl 1(0 1):E169-80. PubMed ID: 24151146
[TBL] [Abstract][Full Text] [Related]
15. Biological specificity of CDK4/6 inhibitors: dose response relationship, in vivo signaling, and composite response signature.
Knudsen ES; Hutcheson J; Vail P; Witkiewicz AK
Oncotarget; 2017 Jul; 8(27):43678-43691. PubMed ID: 28620137
[TBL] [Abstract][Full Text] [Related]
16. α-Mangostin suppresses the viability and epithelial-mesenchymal transition of pancreatic cancer cells by downregulating the PI3K/Akt pathway.
Xu Q; Ma J; Lei J; Duan W; Sheng L; Chen X; Hu A; Wang Z; Wu Z; Wu E; Ma Q; Li X
Biomed Res Int; 2014; 2014():546353. PubMed ID: 24812621
[TBL] [Abstract][Full Text] [Related]
17. All-trans-retinoid acid induces the differentiation of P19 cells into neurons involved in the PI3K/Akt/GSK3β signaling pathway.
Fu F; Li LS; Li R; Deng Q; Yu QX; Yang X; Pan M; Han J; Zhen L; Zhang LN; Lei TY; Li DZ; Liao C
J Cell Biochem; 2020 Nov; 121(11):4386-4396. PubMed ID: 31961017
[TBL] [Abstract][Full Text] [Related]
18. HOXB5 promotes proliferation, migration, and invasion of pancreatic cancer cell through the activation of the GSK3β/β-catenin pathway.
Gao Y; Fei X; Kong L; Tan X
Anticancer Drugs; 2020 Sep; 31(8):828-835. PubMed ID: 32796404
[TBL] [Abstract][Full Text] [Related]
19. Cleavage and polyadenylation-specific factor 3 induces cell cycle arrest via PI3K/Akt/GSK-3β signaling pathways and predicts a negative prognosis in hepatocellular carcinoma.
Li N; Jiang S; Fu R; Lv J; Yao J; Mai J; Hua X; Chen H; Liu J; Lu M
Biomark Med; 2021 Apr; 15(5):347-358. PubMed ID: 33666519
[No Abstract] [Full Text] [Related]
20. MTA1 promotes epithelial to mesenchymal transition and metastasis in non-small-cell lung cancer.
Ma K; Fan Y; Dong X; Dong D; Guo Y; Wei X; Ning J; Geng Q; Wang C; Hu Y; Li M; Niu W; Li E; Wu Y
Oncotarget; 2017 Jun; 8(24):38825-38840. PubMed ID: 28418915
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
